ENDO-205

ENDO-205 is an investigational, non-hormonal, disease-modifying therapeutic developed for the treatment of endometriosis and potentially endometrial cancer. It is designed to selectively target and eradicate diseased endometriosis tissue without affecting healthy tissue. Unlike current hormonal or surgical treatments, ENDO-205 aims to provide a curative approach by clearing all lesions with a short-term course (up to 3 months), thereby reducing recurrence rates and eliminating the need for long-term medication or surgery. The drug works by being absorbed only in endometriosis tissue and inhibiting a major non-hormonal root cause of pathogenicity, leading to lesion eradication[1][2][3][4].